UNSPSC 51372119: Dihydrocodeine tartrate

This classification denotes an opioid receptor agonist and opioid with the molecular formula C18H23NO3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8LXS95BSA9, chemically known as 7, 8-dihydrocodeine but more generally known as dihydrocodeine bitartrate, which bears US NIH Compound Identifier 3063. European Medicines Agency schedules Dihydrocodeine bitartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01704MIG.

Most nations, for tariff and trade purposes, schedule dihydrocodeine tartrate under HS 29391100. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](CC[C@H]3[C@H]1C5)O)OC.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51372119 Dihydrocodeine tartrate is a Commodity code covering pharmaceutical products, but recent state and local procurement activity tagged under this code shows minimal direct relevance to the code's specific scope. The three most recent opportunities include a Seminole County, Florida IFB for naloxone and drug deactivation systems (a community health initiative unrelated to dihydrocodeine), a Texas Health and Human Services Commission RFI exploring direct-to-manufacturer prescription programs (exploratory market research with no product specification), and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers across multiple states. State and local issuers sourcing under this code span county health departments, state health agencies, and cooperative purchasing organizations, though the current posting record does not demonstrate sustained demand focused on dihydrocodeine tartrate specifically.

The geographic spread of recent activity includes Florida, Texas, and Minnesota, with MMCAP's cooperative framework extending to Oregon and other participating jurisdictions. The Minnesota MMCAP RFP, due March 26, 2026, represents the most directly relevant recent procurement—an RFP establishing multi-award contracts for pharmaceutical manufacturers to supply products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with pricing evaluation weighted 75 percent toward competitiveness and contract terms effective July 1, 2026. Vendors must certify cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two of three authorized wholesalers, and carry commercial general liability of $5 million per occurrence. The code shows little evidence of concentrated or recurring activity narrowly focused on dihydrocodeine tartrate; state and local procurement under this code appears to be episodic and driven by broader pharmaceutical category sourcing rather than demand for a specific controlled-substance formulation.